NOVAVAX INC Marketable Securities (Current)
NOVAVAX INC (NVAX) had Marketable Securities (Current) of $527.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $527.88M.
- 2026-03-31: Marketable Securities, Current $561.97M.
- 2025-12-31: Marketable Securities, Current $494.45M.
- 2025-09-30: Marketable Securities, Current $494.87M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $527.88M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $561.97M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $494.45M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $494.87M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $358.56M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $468.14M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $392.89M 10-K · filed 2026-02-26 |
| 2024-09-30 | $335.90M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $369.43M 10-Q · filed 2024-08-08 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.25M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $157.65M 10-K · filed 2022-03-01 |
| 2020-09-30 | $169.86M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $77.90M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $57.47M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 |
| 2019-03-31 | $2.48M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $21.98M 10-K · filed 2020-03-11 |
| 2018-09-30 | $70.61M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $78.64M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $30.36M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $51.00M 10-K · filed 2019-03-18 |
| 2017-09-30 | $68.32M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $111.52M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $115.33M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $91.13M 10-K · filed 2018-03-14 |
| 2016-09-30 | $180.34M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $276.97M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $301.64M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $137.55M 10-K · filed 2017-02-27 |
| 2015-09-30 | $152.04M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $147.55M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $112.69M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $135.72M 10-K · filed 2016-02-29 |
| 2013-12-31 | $13.60M 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |